Britain picks Glaxo's Cervarix for vaccine program
LONDON, June 18
LONDON, June 18 (Reuters) - GlaxoSmithKline's (GSK.L) cervical cancer vaccine Cervarix was picked as the medicine of choice for the British Department of Health's immunisation program, the drugmaker said on Wednesday.
The program aims to protect against the two types of human papillomavirus responsible for about 70 percent of cervical cancers and starts in September for girls aged 12 to 13, the company said.
The decision marks a defeat for Merck's (MRK.N) Gardasil, which competes with the Glaxo drug. (Reporting by Michael Kahn)
- Tweet this
- Share this
- Digg this
- Nearly 300 missing after South Korean ferry capsizes - coastguard
- Separatists fly Russian flag over Ukrainian armoured vehicles |
- Battle over Scottish independence slightly tightens in new poll
- Unemployment plunges to five-year low, pay grows
- Tesco to step up price cuts as CEO defies pressure to quit |